Pip-tazo causes mortality over cefepime, researchers loudly claim
What conclusions does this widely shared paper actually support?
A retrospective observational study based on a “natural experiment” during a piperacillin-tazobactam shortage in 2015-2016 at the University of Michigan (forcing increased use of cefepime instead of pip-tazo) concluded that for every 20 patients treated with pip-tazo instead of cefepime, one dies as a result.
You might say, wait— didn’t ACORN show nomina…
Keep reading with a 7-day free trial
Subscribe to PulmCCM to keep reading this post and get 7 days of free access to the full post archives.